Amit Verma

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1241199/publications.pdf

Version: 2024-02-01

23	915	687363 13	610901 24
papers	citations	h-index	g-index

24	24	24	1937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 2019, 25, 103-110.	30.7	169
2	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
3	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. ELife, 2019, 8, .	6.0	103
4	Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica, 2014, 99, 930-936.	3.5	59
5	Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease. Nature Communications, 2019, 10, 2461.	12.8	59
6	Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer. Journal of Biological Chemistry, 2017, 292, 837-846.	3.4	43
7	Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes. Seminars in Hematology, 2013, 50, 16-37.	3.4	42
8	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	9.4	41
9	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood, 2020, 135, 191-207.	1.4	40
10	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal, 2021, 11, 157.	6.2	27
11	Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle, 2014, 13, 3320-3327.	2.6	26
12	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of Clinical Oncology, 2021, 39, 1001-1009.	1.6	22
13	VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. Nature Cell Biology, 2022, 24, 290-298.	10.3	19
14	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine, 2022, 28, 468-471.	30.7	19
15	Therapeutic targeting of the inflammasome in myeloid malignancies. Blood Cancer Journal, 2021, 11, 152.	6.2	17
16	HIV portends a poor prognosis in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3529-3535.	1.3	15
17	Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances, 2022, 6, 1152-1161.	5.2	13
18	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	5.2	12

#	Article	IF	Citations
19	Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis. Leukemia, 2020, 34, 1689-1693.	7.2	12
20	Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. Leukemia and Lymphoma, 2019, 60, 3132-3137.	1.3	5
21	Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor. Leukemia and Lymphoma, 2016, 57, 2452-2455.	1.3	2
22	The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. Leukemia and Lymphoma, 2020, 61, 2453-2465.	1.3	1
23	A needed boost against COVID-19 in lymphoma. Nature Cancer, 2022, 3, 526-527.	13.2	1